Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CLOBAZAM

All products: Limited Use (codes 23)

Teva-Clobazam · DIN 02238334 · 10mg · tablet

Limited Use — Reason for Use code 23 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 23 required
Write on scriptLU code 23 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 23
Reason for Use code 23 As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory. Coverage limit: Because a large number of patients will become refractory to the anticonvulsant effects of the drug over a period of time, the effectiveness of this drug must be re-evaluated after a period of six months. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Clobazam · DIN 02238334 Manufacturer: Teva Canada Limited; listing date 1999-04-15 Health Canada: Marketed since 2017-01-10 · brand TEVA-CLOBAZAM · ATC N05BA09 CLOBAZAM · form Tablet · route Oral · ingredients CLOBAZAM 10 MG · company Teva canada limited · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Teva-Clobazam: Formulary list price $0.2197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61740 · Verify on the e-Formulary ↗ (DIN 02238334)

Source record
DIN 02238334: Teva-Clobazam Raw flags: sec12=Y, sec3=Y Item: 281200061; group id 425; item number 1058; lccId 00071; manufacturer id TEV Source form: Tab; strength: 10mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.2197; ministry $0.2197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238334 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61740
Interchangeable products
Apo-Clobazam · DIN 02244638 · $0.2197 Frisium · DIN 02221799 · not recorded
Shortage status: resolved shortage (ended 2026-04-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238334
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

GABAPENTIN

· 69 products · General benefit (49), Off-Formulary Interchangeable, not an ODB benefit (20) · strengths: 100mg, 300mg, 400mg, 600mg, 800mg · Cap, Tab

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free)

PREGABALIN

· 102 products · General benefit (93), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 25mg, 50mg, 75mg, 150mg, 225mg, 300mg · Cap

PRIMIDONE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 125mg, 250mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

VALPROATE SODIUM

· 5 products · General benefit · strengths: 50mg/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-CLOBAZAM (clobazam) is indicated for: adjunctive therapy in patients with epilepsy who are not adequately stabilized with their current anticonvulsant therapy. Geriatrics (> 65 years of age): The efficacy of TEVA-CLOBAZAM in adults aged 65 and over has not been established (see WARNINGS AND PRECAUTIONS and ACTION AND CLINICAL PHARMACOLOGY sections). Long-term use of TEVA-CLOBAZAM should be avoided in elderly patients. Enhanced monitoring is recommended (see WARNINGS AND PRECAUTIONS, Falls and fractures; DOSAGE AND ADMINISTRATION, Dosing considerations). https://pdf.hres.ca/dpd_pm/00064104.PDF PM date: December 22, 2021 Source product: TEVA-CLOBAZAM; DIN 02238334; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.